Cyclacel Pharmaceuticals (CYCC) Stock Climbs On Phase 1 Data


Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)

Cyclacel Pharmaceuticals is having an incredible day in the market today, and for good reason. Early this morning, the company reported Phase 1 data surrounding one of its lead candidates, and that data was overwhelmingly positive. Today, we’ll talk about what we saw, how the market reacted to the news, and what we can expect to see from CYCC moving forward.

Trade smarter and make more money with Tradespoon!

CYCC Releases Positive Phase 1 Data

As mentioned above, Cyclacel Pharmaceuticals is having a strong day in the market today after releasing data from its Phase 1 trial addressing DNA damage response. The program is evaluating a combination treatment that combines two CYCC candidates known as seliciclib and sapacitabine. Seliciclib is a cyclin-dependent kinase inhibitor while sapacitabine is a nucleoside analogue. During the study, 45 patients with breast, ovarian, and pancreatic cancers, who tested positive for BRCA mutations, were treated. The results showed a meaningful improvement and strong response to he treatment. More data will soon be offered during an oral presentation at the 2016 American Society of Clinical Oncology annual meeting.

During the announcement, several key figures close to the study had comments to offer. Here’s what they had to say:

We are encouraged by the durable responses and stable disease seen with the seliciclib and sapacitabine combination in patients with BRCA mutations, in particular because most were heavily pretreated and many are able to remain on study for extended periods… Our findings from Parts 1 and 2 of the study have shown that the orally-administered regimen is well tolerated with manageable toxicities. Based on the results, we believe that further clinical evaluation of this combination regimen is warranted. A Part 3 extension of the study is currently enrolling advanced breast cancer patients with BRCA mutations.” – Sara M. Tolaney, M.D., M.P.H., Associate Director of Clinical Research and Breast Oncology at the Dana-Farber Cancer Institute in Boston.

The findings reported in Dr. Tolaney’s presentation show that the combination treatment of seliciclib and sapacitabine is active and tolerable… This clinical observation may be directly related to the drug’s interference with the capacity of BRCA-mutated cancer cells to repair and survive sapacitabine-included breaks in their DNA. If these preliminary findings are confirmed by further data, this regimen may provide an important treatment options for patients with BRCA-mutated cancers.” – Judy Chiao, M.D., Vice President of Clincal Development and Regulatory Affairs at CYCC.

The ASCO data built on earlier data from our DNA damage response program highlighted by the American Association for Cancer Research Annual Meeting Program Committee in a 2013 press conference… The updated data support and extend clinical evidence of efficacy with different schedules of the combination in this patient population. We are encouraged with the durability of responses and stable disease, with ongoing responding patients achieving treatment durations exceeding 1 and 4.5 years respectively. We look forward to reporting data from the ongoing Part 3 extension in BRCA positive patients with breast cancer and increasing our understanding of the potential benefit of this differentiated treatment strategy in a targeted patient population with significant unmet medical need.” – Spiro Rombotis, President and CEO at CYCC.

How The Market Reacted To The News

One of the first things that new-comer investors learn is that the news moves the market. When positive news is released, we can expect gains and when negative news is released, we can expect declines. In this particular case, the news released by Cyclacel Pharmaceuticals was overwhelmingly positive. So, it’s only natural that we’re seeing strong upward movement on the stock. Currently (12:04), the stock is trading at $7.18 per share after a gain of $2.78 per share, or 63.10%, thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from CYCC. The news that was released today shows that the company is now one step closer to meeting a dire unmet medical need. As trials continue and show positivity, the profitability surrounding the treatment becomes more apparent. All in all, I’m expecting to see further growth.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think CYCC is headed moving forward and why? Join the discussion at the new TalkTRENDZ from CNA Finance!

[Image Courtesy of Pixabay]


Please enter your comment!
Please enter your name here